The Magazine for Sleep Professionals
Thursday, February 5, 2026
Bedfont Scientific Ltd., is celebrating a brighter 2022 as the U.S. Food and Drug Administration (FDA) cleared its NObreath FeNO monitor for use in monitoring airway inflammation. The NObreath®, which conforms to ATS and ERS guidelines1, is a portable, non-invasive device for the measurement of Fractional Exhaled Nitric Oxide (FeNO) […]
In its latest clinical practice guideline on evaluation and treatment of asthma, an American Thoracic Society expert guidelines panel has addressed the use of fractional exhaled nitric oxide (FeNO) to guide the treatment of asthma. The guideline was published online in the Nov. 15 issue of the American Journal of Respiratory and Critical […]
CAIRE Inc. has announced the acquisition of Spirosure, Inc. Spirosure is a California-based developer and manufacturer of innovative technology for measuring Fractional Exhaled Nitric Oxide (FeNO), a key indicator of allergic inflammation in asthmatic patients. It is estimated that asthma affects more than 300 million individuals worldwide and recent Global […]
Spirosure Inc. announced that it has made an FDA 510(k) submission seeking U.S. clearance for its Fenom PRO Point-of-Care Breathalyzer, which was launched in September at the world’s largest meeting for respiratory physicians, scientists and allied health professionals: the European Respiratory Society (ERS) International Congress 2017. Fenom PRO is CE […]
